<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276119</url>
  </required_header>
  <id_info>
    <org_study_id>RA0001</org_study_id>
    <nct_id>NCT01276119</nct_id>
  </id_info>
  <brief_title>The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-center, Single-dose, Dose-escalating Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of CDP6038 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability, blood levels and effects of CDP6038 administered by
      intravenous infusion (iv) and subcutaneous (sc) injection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum drug concentration (Cmax) of CDP6038 in plasma given by intravenous (iv) infusion and subcutaneous (sc) injection in healthy male subjects.</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration/time curve from hour 0 to the time with the last quantifiable level of CDP6038 given by iv infusion and sc injection in healthy male subjects.</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration/time curve extrapolated to infinity, of CDP6038 given by iv infusion and sc injection in healthy male subjects.</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The half life of CDP6038 in plasma given by iv infusion and sc injection in healthy male subjects.</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The apparent volume of distribution of CDP6038 given by iv infusion and sc injection in healthy male subjects.</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total body clearance of CDP6038 in plasma given by iv infusion and sc injection in healthy male subjects.</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK/PD relationship between systemic CDP6038 exposure and suppression of selected acute phase markers (such as C-reactive protein) following CDP6038 administration by iv infusion and sc injection in healthy male subjects.</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-CDP6038 antibodies in plasma following iv infusion and sc injection of CDP6038 in healthy male subjects.</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Cohort A, CDP6038 0.001 mg/kg, iv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B, CDP6038 0.01 mg/kg, iv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C, CDP6038 0.03 mg/kg, iv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D, CDP6038 0.1 mg/kg, iv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E, CDP6038 0.3 mg/kg, iv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort G, CDP6038 1.0 mg/kg, iv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort I, CDP6038 3.0 mg/kg, iv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort K, CDP6038 10.0 mg/kg, iv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A, Placebo, iv</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B, C, D, E, G, I, K, Placebo, iv</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F, CDP6038 0.3 mg/kg, sc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort H, CDP6038 1.0 mg/kg, sc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort J, CDP6038 3.0 mg/kg, sc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F, H, J, Placebo, sc</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CDP6038</intervention_name>
    <description>100 mg/mL solution for injection Single infusion over 60 minutes</description>
    <arm_group_label>Cohort A, CDP6038 0.001 mg/kg, iv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CDP6038</intervention_name>
    <description>100 mg/mL solution for injection Single infusion over 120 minutes</description>
    <arm_group_label>Cohort B, CDP6038 0.01 mg/kg, iv</arm_group_label>
    <arm_group_label>Cohort C, CDP6038 0.03 mg/kg, iv</arm_group_label>
    <arm_group_label>Cohort D, CDP6038 0.1 mg/kg, iv</arm_group_label>
    <arm_group_label>Cohort E, CDP6038 0.3 mg/kg, iv</arm_group_label>
    <arm_group_label>Cohort G, CDP6038 1.0 mg/kg, iv</arm_group_label>
    <arm_group_label>Cohort I, CDP6038 3.0 mg/kg, iv</arm_group_label>
    <arm_group_label>Cohort K, CDP6038 10.0 mg/kg, iv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CDP6038</intervention_name>
    <description>100 mg/mL solution for injection Single sc injection</description>
    <arm_group_label>Cohort F, CDP6038 0.3 mg/kg, sc</arm_group_label>
    <arm_group_label>Cohort H, CDP6038 1.0 mg/kg, sc</arm_group_label>
    <arm_group_label>Cohort J, CDP6038 3.0 mg/kg, sc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride for injection Single infusion over 60 minutes</description>
    <arm_group_label>Cohort A, Placebo, iv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride for injection Single infusion over 120 minutes</description>
    <arm_group_label>Cohort B, C, D, E, G, I, K, Placebo, iv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride for injection Single sc injection</description>
    <arm_group_label>Cohort F, H, J, Placebo, sc</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index between 19.0 and 28.0 kg/m² and body weight between ≥ 50 kg and ≤ 120
             kg

        Exclusion Criteria:

          -  Previous trial participation or blood donation/loss within 3 months

          -  Subject is not healthy (eg significant medical history, taking drug treatments, any
             psychological or emotional problems, or drug or alcohol abuse (current or historical)

          -  Plans for or actual vaccination within 3 months

          -  Previous drug treatments

          -  Tobacco use or heavy caffeine consumption

          -  Systolic blood pressure &lt;90 or &gt;145mmHg, diastolic blood pressure &lt;40 or &gt;90mmHg or
             heart rate &lt;45 or &gt;90 beats per minute
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2011</study_first_submitted>
  <study_first_submitted_qc>January 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2011</study_first_posted>
  <last_update_submitted>March 21, 2012</last_update_submitted>
  <last_update_submitted_qc>March 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CDP6038</keyword>
  <keyword>single-dose</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>healthy subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

